Regenxbio

Yahoo Finance • 28 days ago

REGENXBIO Reports Positive Data From Phase I/II/III CAMPSIITE Trial Of RGX-121

(RTTNews) - REGENXBIO Inc. (RGNX) announced positive data from the Phase I/II/III CAMPSIITE trial of clemidsogene lanparvovec or RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II, also known as Hunter syndrome. Prima... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 2 months ago

REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls

REGENXBIO INC (NASDAQ:RGNX [https://www.chartmill.com/stock/quote/RGNX]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company posted revenue of $21.36 mi... Full story

Yahoo Finance • 2 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 Pivotal trial enrollment accelerated, expected to complete in October 2025 ahead of previous guidance Clemidsogene lanparvovec (RGX-12... Full story

Yahoo Finance • 2 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

A pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiated New Phase II ALTITUDE® trial data demonstrate a durable safety and efficacy profile observed through two years wit... Full story

Yahoo Finance • 2 months ago

Sarepta Therapeutics' SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of $1.36 billion and a stock th... Full story

Yahoo Finance • 2 months ago

REGENXBIO Inc. (RGNX): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap. We came across a bullish the... Full story

Yahoo Finance • 3 months ago

REGENXBIO's gene therapy with CT domain shows improved muscle function in study

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX), a biotechnology company whose stock has gained over 22% in the past six months and is currently considered undervalued according to InvestingPro analysis, published preclinical research Thursd... Full story

Yahoo Finance • 3 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid challenges

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company focused on developing gene therapies for rare diseases, has garnered significant attention from investors and analysts alike. The company’s lead candidate, SGT-003, for the tre... Full story

Yahoo Finance • 4 months ago

Solid Biosciences' SWOT analysis: gene therapy stock shows promise amid DMD competition

Solid Biosciences Inc. (NASDAQ:SLDB), a biotechnology company with a market capitalization of $350 million focused on developing gene therapies for rare diseases, has been making significant strides in its pursuit of treatments for Duchen... Full story

Yahoo Finance • 5 months ago

Q1 2025 Regenxbio Inc Earnings Call

Participants Patrick Christmas; Chief Legal Officer; Regenxbio Inc Curran Simpson; President, Chief Executive Officer and Board Member; Regenxbio Inc Stephen Pakola; Executive Vice President, Chief Medical Officer; Regenxbio Inc Mitche... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the t... Full story

Yahoo Finance • 2 years ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

Kenneth Mills, President and CEO of Regenxbio Inc (NASDAQ:RGNX), executed a sale of 45,000 shares in the company on December 19, 2023, according to a recent SEC Filing. Regenxbio Inc is a biotechnology company focused on the development, c... Full story

Yahoo Finance • 2 years ago

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript November 8, 2023 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.41, expectations were $-1.44. Operator: Good day, and thank you for standing by. Welcome to RE... Full story

Yahoo Finance • 2 years ago

REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results

Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest priority programs are ABBV-RGX-314 for the... Full story

Yahoo Finance • 3 years ago

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter and full year e... Full story

Yahoo Finance • 3 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duch... Full story

Yahoo Finance • 3 years ago

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. 41st Annual J.P. Morgan Healthcare Conferen... Full story

Yahoo Finance • 3 years ago

Rockville's RegenxBio lays out potential path to market for its first gene therapy treatments

For RegenxBio Inc., a Rockville biotech that's made millions from royalty revenue over the years, 2023 will be critical to its ability to start selling its own commercial product for the first time. The 13-year-old company, which went publ... Full story

Yahoo Finance • 3 years ago

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022: Panel: Unique Delivery Te... Full story